Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.43 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.43 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 2/20 | 0.43 |
| ▸ | ACE | P12821 | 5/20 | 0.41 |
| ▸ | MME | P08473 | 1/20 | 0.40 |
| ▸ | REN | P00797 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | LAP3 | P28838 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7384926 | 0.97 | ANPEP (0.44) | ANPEPRNPEPDNPEPMMP1ACE | |
| SCHEMBL8764855 | 0.85 | MMP1 (0.48) | ANPEPRNPEPDNPEPMMP1ACE | |
| SCHEMBL8763008 | 0.81 | ANPEP (0.42) | ANPEPRNPEPDNPEPMMP1ACE | |
| SCHEMBL8764118 | 0.81 | LTA4H (0.38) | ANPEPRNPEPDNPEPMMP1ACE | |
| SCHEMBL7384535 | 0.79 | ELANE (0.44) | ANPEPRNPEPDNPEPMMP1ACE | |
| SCHEMBL7427977 | 0.79 | REN (0.40) | ANPEPRNPEPDNPEPMMP1REN | |
| SCHEMBL7999637 | 0.78 | ANPEP (0.51) | ANPEPRNPEPDNPEPACEREN | |
| SCHEMBL6414041 | 0.77 | MME (0.48) | ANPEPRNPEPDNPEPMMP1ACE | |
| SCHEMBL27468737 | 0.77 | ANPEP (0.53) | ANPEPRNPEPDNPEPACEMME | |
| SCHEMBL7427886 | 0.76 | MMP1 (0.47) | MMP1ACEMMEREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | disclosed |
| EP-1047450-A1 | ACE INHIBITOR-MMP INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 2000-11-02 | — | — | EP | disclosed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | disclosed |
| EP-0946166-A1 | USE OF MATRIX METALLOPROTEINASE INHIBITORS FOR TREATING NEUROLOGICAL DISORDERS AND PROMOTING WOUND HEALING | WARNER-LAMBERT COMPANY (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1999032150-A1 | ACE INHIBITOR-MMP INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 1999-07-01 | — | — | WO | disclosed |
| WO-1998026773-A1 | USE OF MATRIX METALLOPROTEINASE INHIBITORS FOR TREATING NEUROLOGICAL DISORDERS AND PROMOTING WOUND HEALING | WARNER-LAMBERT COMPANY (US) | 1998-06-25 | — | — | WO | disclosed |